Adagene Inc.
ADAG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818838
In the last 90 days, Adagene Inc. insiders filed 4 open-market purchases and 0 sales; 35 institutions reported holding it in 13F filings for Q2 2026, worth $81.0M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Adagene Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 11 | 17 | +6 |
| Shares | 7.12M | 12.3M | +5.17M (+72.6%) |
| Value | $15.5M | $34.3M | +$18.8M (+121.3%) |
New holders (6)
Institutions that held Adagene Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| FIL Ltd | 3,844,836 | $10.8M | 0.01% |
| Barclays PLC | 175,130 | $490.4K | 0.00% |
| Exome Asset Management LLC | 155,383 | $435.1K | 0.37% |
| Prelude Capital Management, LLC | 28,620 | $80.1K | 0.01% |
| Millennium Management LLC | 15,181 | $42.8K | 0.00% |
| Citadel Advisors LLC | 12,995 | $36.6K | 0.00% |
Sold out (0)
Institutions that held Adagene Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
None.